<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02777619</url>
  </required_header>
  <id_info>
    <org_study_id>Pharmacodynamic Interactions</org_study_id>
    <nct_id>NCT02777619</nct_id>
  </id_info>
  <brief_title>Pharmacodynamic Interactions of Propofol and Dexmedetomidine on Intravenous Anesthesia</brief_title>
  <acronym>PIPDIA</acronym>
  <official_title>Pharmacodynamic Interactions of Propofol and Dexmedetomidine on Target-controlled Infusion Intravenous Anesthesia During the Induction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangzhou General Hospital of Guangzhou Military Command</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guangzhou General Hospital of Guangzhou Military Command</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine pharmacodynamic interactions of propofol and
      dexmedetomidine,exploring the effect of dexmedetomidine on propofol unconsciousness median
      effective concentration (EC50).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      64 cases were randomly divided into four groups, In each group, dexmedetomidine target plasma
      concentration are 0, 0.4, 0.6, 0.8 ng/ml. Dexmedetomidine administered 15 min before target
      controlled infusion of propofol. The propofol infusion was started to provide a target
      effect-site concentration of 1.0ug/ml, and increased by 0.2ug/ml until loss of consciousness
      when the effect-site concentration and target concentration equilibrium.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The EC50 of propofol for loss of consciousness</measure>
    <time_frame>within 30 min during the induction of anesthesia</time_frame>
    <description>The aim of the investigators study is to define the optimum target concentration (EC50) of propofol for loss of consciousness with different dexmedetomidine target plasm concentration.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The EC95 of propofol for loss of consciousness</measure>
    <time_frame>within 30 min during the induction of anesthesia</time_frame>
    <description>The aim of the investigators study is to define the optimum target concentration (EC95) of propofol for loss of consciousness with different dexmedetomidine target plasm concentration.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Pharmacodynamic Interaction</condition>
  <arm_group>
    <arm_group_label>Propofol and 0.0ng/ml Dexmedetomidine</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Propofol infusion was started to provide an effect-site concentration of 1.0ug/ml after Dexmedetomidine which target plasma concentration is 0.0ng/ml administered for 15min, and increased by 0.2ug/ml until the patient's consciousness disappears.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Propofol and 0.4ng/ml Dexmedetomidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Propofol infusion was started to provide an effect-site concentration of 1.0ug/ml after Dexmedetomidine which target plasma concentration is 0.4ng/ml administered for 15min, and increased by 0.2ug/ml until the patient's consciousness disappears.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Propofol and 0.6ng/ml Dexmedetomidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Propofol infusion was started to provide an effect-site concentration of 1.0ug/ml after Dexmedetomidine which target plasma concentration is 0.6ng/ml administered for 15min, and increased by 0.2ug/ml until the patient's consciousness disappears.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Propofol and 0.8ng/ml Dexmedetomidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Propofol infusion was started to provide an effect-site concentration of 1.0ug/ml after Dexmedetomidine which target plasma concentration is 0.8ng/ml administered for 15min, and increased by 0.2ug/ml until the patient's consciousness disappears.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.0ng/ml Dexmedetomidine</intervention_name>
    <description>Dexmedetomidine target plasma concentration is 0.0ng/ml</description>
    <arm_group_label>Propofol and 0.0ng/ml Dexmedetomidine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.4ng/ml Dexmedetomidine</intervention_name>
    <description>Dexmedetomidine target plasma concentration is 0.4ng/ml</description>
    <arm_group_label>Propofol and 0.4ng/ml Dexmedetomidine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.6ng/ml Dexmedetomidine</intervention_name>
    <description>Dexmedetomidine target plasma concentration is 0.6ng/ml</description>
    <arm_group_label>Propofol and 0.6ng/ml Dexmedetomidine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.8ng/ml Dexmedetomidine</intervention_name>
    <description>Dexmedetomidine target plasma concentration is 0.8ng/ml</description>
    <arm_group_label>Propofol and 0.8ng/ml Dexmedetomidine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol</intervention_name>
    <arm_group_label>Propofol and 0.0ng/ml Dexmedetomidine</arm_group_label>
    <arm_group_label>Propofol and 0.4ng/ml Dexmedetomidine</arm_group_label>
    <arm_group_label>Propofol and 0.6ng/ml Dexmedetomidine</arm_group_label>
    <arm_group_label>Propofol and 0.8ng/ml Dexmedetomidine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Weight:18≦ BMI≦25

          2. Written informed consent from the patient or the relatives of the participating
             patient.

        Exclusion Criteria:

          1. A previous history of intolerance to the study drug or related compounds and
             additives.

          2. Existing significant haematological, endocrine, metabolic or gastrointestinal disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Guangzhou Military Region General Hospital, Department of Anesthesiology</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510010</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Chen Z, Shao DH, Hang LH. Effects of dexmedetomidine on performance of bispectral index as an indicator of loss of consciousness during propofol administration. Swiss Med Wkly. 2013 Mar 14;143:w13762. doi: 10.4414/smw.2013.13762.</citation>
    <PMID>23519436</PMID>
  </reference>
  <reference>
    <citation>Hannivoort LN, Eleveld DJ, Proost JH, Reyntjens KM, Absalom AR, Vereecke HE, Struys MM. Development of an Optimized Pharmacokinetic Model of Dexmedetomidine Using Target-controlled Infusion in Healthy Volunteers. Anesthesiology. 2015 Aug;123(2):357-67. doi: 10.1097/ALN.0000000000000740.</citation>
    <PMID>26068206</PMID>
  </reference>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 11, 2016</study_first_submitted>
  <study_first_submitted_qc>May 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 19, 2016</study_first_posted>
  <last_update_submitted>July 27, 2016</last_update_submitted>
  <last_update_submitted_qc>July 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Guangzhou General Hospital of Guangzhou Military Command</investigator_affiliation>
    <investigator_full_name>bo xu</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Pharmacodynamic</keyword>
  <keyword>Dexmedetomidine</keyword>
  <keyword>Propofol</keyword>
  <keyword>Target-controlled Infusion Intravenous Anesthesia</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

